Luxturna Onetime Gene Therapy for Biallelic RPE65 MutationAssociated Retinal Dystrophy

############################# Video Source: www.youtube.com/watch?v=ztBMgIW_g8Y

Ron Philip, Chief Commercial Officer of Spark Therapeutics, discusses his company's first approved product, Luxturna -- a one-time gene therapy indicated for...

CheckRare, CheckOrphan, Ron Philip, Spark Therapeutics, Luxturna, inherited retinal disease, IRD, www.eyewant2know.com, biallelic RPE65 mutations, adeno-associated virus
#############################